Schnitzler Syndrome
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
2100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
SandozAustria - Kundl
2 programs2
CanakinumabPhase 2Monoclonal Antibody1 trial
CanakinumabPhase 2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Olatec Therapeuticsdapansutrile
SandozCanakinumab
SandozCanakinumab
Clinical Trials (3)
Total enrollment: 30 patients across 3 trials
Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome
Start: May 2018Est. completion: May 20182 patients
Phase 2Terminated
Ilaris® Effects in Schnitzler Syndrome (ILESCH)
Start: Jul 2011Est. completion: May 201820 patients
Phase 2Completed
Efficacy and Safety of Canakinumab in Schnitzler Syndrome
Start: Jan 2011Est. completion: Dec 20118 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Monoclonal Antibody is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.